Dr. James Richard Broughman II, MD

Dr. Broughman practices at Coastal Carolina Radiation Oncology in Wilmington, North Carolina.

Dr. Broughman's NPI, 1053844423, was assigned on April 4, 2017. Dr. Broughman holds North Carolina license 2022-01489.

Dr. Broughman's primary practice is Coastal Carolina Radiation Oncology, at 1988 S 16th St, Wilmington, NC 28401 in New Hanover County. The practice phone is (910) 662-8440.

Dr. Broughman's primary practice is Coastal Carolina Radiation Oncology in Wilmington, North Carolina. Dr. Broughman is also affiliated with Novant Health New Hanover Regional Medical Center. The medical group on file is Coastal Carolina Radiation Oncology Center. Dmand AI also links Dr. Broughman to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Broughman practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Broughman's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Broughman is licensed in North Carolina.

CMS data shows 1,403 Medicare services from Dr. Broughman across 14 procedure codes in 2024, for 206 Medicare patients. Medicare paid $99,898 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 206 Medicare patients who saw Dr. Broughman in 2024. The largest group is 65 to 74, with 106 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Broughman's median patient age at 74, with 46% women.

In 2024, Dr. Broughman wrote 100 Medicare Part D claims for 45 patients. 96% of them were for generic drugs. CMS names the drug for 48 of them, across 2 drugs with 11 or more claims each, at $531 in total drug cost. In 2023, CMS named 28 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Broughman for performance year 2024, reported through an alternative payment model (APM). Dr. Broughman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 31 papers to Dr. Broughman, published from 2013 to 2023. 2016 was the busiest year, with 5. The most frequent topics are Prostatic Neoplasms, Rotavirus and Brachytherapy. Dr. Broughman has published most often in J Virol. Dr. Broughman's most frequent co-authors are Mark Donowitz, MD, Robert L. Atmar, MD and David J. Adelstein, MD.

CMS Open Payments shows 6 general payments to Dr. Broughman from 5 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $151.